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The interaction betweenT-cell receptors (TCRs) and peptide epitopes is highly degenerate:
a TCR is capable of interacting productively with a wide range of different peptide ligands,
involving not only cross-reactivity proper (similar epitopes elicit strong responses), but also
polyspecificity (ligands with distinct physicochemical properties are capable of interacting
with the TCR). Degeneracy does not gainsay the fact that TCR recognition is fundamen-
tally specific: for the vast majority of ligands, the functional sensitivity of a given TCR is
virtually null whereas this TCR has an appreciable functional sensitivity only for a minute
fraction of all possible ligands. Degeneracy can be described mathematically as the proba-
bility that the functional sensitivity, of a given TCR to a randomly selected ligand, exceeds
a set value. Variation of this value generates a statistical distribution that characterizesTCR
degeneracy. This distribution can be modeled on the basis of a Gaussian distribution for
the TCR/ligand dissociation energy. The kinetics of the TCR and the MHCI molecule can
be used to transform this underlying Gaussian distribution into the observed distribution
of functional sensitivity values. In the present paper, the model is extended by accounting
explicitly for the kinetics of the interaction between the co-receptor and the MHCI mole-
cule. We show that T-cells can modulate the level of degeneracy by varying the density of
co-receptors on the cell surface.This could allow for an analog of avidity maturation during
incipient T-cell responses.
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INTRODUCTION
Thymus-derived lymphocytes (T-cells) recognize peptide antigens
via antigen-specific receptors (TCRs); in particular, CD8+ cyto-
toxic T lymphocytes (CTLs) recognize short peptides presented
by major histocompatibility complex (MHC) class I molecules
(1). Estimates of the human TCR diversity suggest that there are
∼108 different antigen receptors in the naïve T-cell pool (2), which
raises the question how such a limited TCR repertoire can provide
effective immunity to perhaps over 1015 distinct pMHCs (2). The
discrepancy suggests that even while TCRs are highly specific, a
considerable degree of degeneracy remains (we use degeneracy as
a term of art to cover both polyspecificity and cross-reactivity).
The central importance of degeneracy was first pointed out by
Mason (3) and later confirmed by others such as (4). Experi-
mental and mathematical studies confirm that TCR recognition
is highly degenerate: a single TCR may be able to recognize, at
physiologically relevant degrees of functional sensitivity, over one
million different peptides in the context of a single MHCI molecule
(2, 5), an estimate that takes into account the binding specificity
of the MHC molecule, but not the additional selection imposed
by the stringency requirements of peptide cleavage and process-
ing in the presentation pathway. The latter constitutes an epitope
diversity filter that is instrumental in regulating the immuno-
visibility of salient epitopes (6). The issue of whether there exists
an optimal level of TCR repertoire diversity was reviewed by
Nikolich-Žuglich et al. (7), and various authors have reviewed
the functional repercussions at the systems level (8–10).
The interaction between TCR and pMHCI ligand can be mod-
ulated by the co-receptor CD8 in several ways: (i) promoting the
association of TCR and pMHCI; (ii) stabilizing the TCR/pMHCI
interaction; and (iii) enhancing the rate at which the TCR/CD3
complex attains signaling status by association of TCR/CD3 with
protein tyrosine kinases such as p56lck and adaptor molecules such
as LAT and LIME (5, 11–16). The first of these three mechanisms
modifies the affinity of the TCR/pMHCI interaction, whereas the
third alters the time it takes for an engaged TCR/CD3 com-
plex to attain full signalosome status. In particular, CD8 can
enhance the TCR/pMHCI association rate by 50%, and reduce
the TCR/pMHCI dissociation rate by at least 50% (16, 17), and
CD8 modulates the rate of immune receptor tyrosine-based acti-
vation motif (ITAM) phosphorylation, by recruiting TCR/pMHCI
complexes to membrane micro-domains at a rate which depends
on the affinity of pMHCI/CD8 binding (16).
These findings suggest that CD8 not only controls degener-
acy, but also differentially regulates functional sensitivity, that is,
the T-cell can increase its sensitivity for one ligand, while reduc-
ing it for others. By varying the level of CD8 expression, the
T-cell can increase its sensitivity to the disease-associated antigen,
while at the same time decreasing its sensitivity to antigens asso-
ciated with healthy conditions. This novel mode of co-receptor
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action could be critical in ensuring that the TCR repertoire retains
the ability to respond to antigenic challenges, while avoiding
autoimmunity.
T-cell antigen recognition can be expressed in terms of its func-
tional sensitivity (18). One of the main determinants of functional
sensitivity is the rate at which a single agonist copy elicits TCR
triggering. Functional sensitivity depends on bio-molecular para-
meters such as the TCR/pMHCI on-rate and off-rate. The mole-
cular kinetics at the T-cell:antigen-presenting cell (APC) interface
determine this relationship. This kinetic theory resolves the long-
standing controversy over whether T-cell activation is governed
by affinity or off-rate (cf. (19, 20)); the theory shows that both
parameters play a role, but in the so-called MHC-limited regime,
the off-rate is the main governing factor. However, the on-rate
and the off-rate together determine whether or not the kinetics is
MHC-limited (21–23).
The aim of the present study is to explore the kinetic basis
of the role of CD8 in regulating degeneracy and functional sen-
sitivity. Our model generalizes the classical kinetic proofreading
model, as proposed by McKeithan (24), and later modified by
others (21, 22, 25–27). The kinetic proofreading model assumes
that the TCR needs to remain bound to a pMHC in order for the
TCR/CD3 complex to become fully activated, via several modifi-
cation steps such as phosphorylation of several tyrosine residues
on the TCR complex, and recruitment and subsequent activation
of ZAP-70 (28).
The statistics of TCR degeneracy is modeled by relating the
TCR/pMHCI mean interaction time with the dissociation energy
according to Arrhenius theory. We show that by varying the total
co-receptor density and key kinetic parameters, the T-cell can
modulate the level of degeneracy. Furthermore, we compare our
results with experimental data for HLA A∗0201 mutants with
altered binding affinity for CD8.
THEORY: TCR/pMHCI/CD8 KINETICS AND TCR DEGENERACY
We assume (i) that the TCR/CD3 complex on the T-cell sur-
face becomes triggered (achieves signalosome status) during an
interaction with a pMHCI ligand if it undergoes n ITAM phos-
phorylations, where n is a positive integer; and (ii) that the
presence of a CD8 molecule bound to the pMHCI ligand affects
the TCR/pMHCI association and dissociation rates, as well as
the rate at which the TCR/CD3 complex progresses through
the phosphorylation sequence. The co-receptor CD8 is associ-
ated with TCR/CD3 with tyrosine kinases such as p56lck, which
phosphorylates tyrosine residues within the ITAMs.
To determine the kinetics of the TCR/pMHCI/CD8 inter-
actions, consider the four binding states of a pMHCI mole-
cule, labeled (I–IV) in Figure 1A. The states in which the TCR
and the pMHCI ligand are bound can be further subdivided
into different states according to the number of phosphorylated
ITAMs, as shown in Figure 1B. The transition rate between
these states is n/TR, where TR is the average time required to go
through the entire sequence. The notation TR emphasizes that
this quantity is the average time for the TCR/CD3 complex to
become triggered. We call this the TCR triggering threshold. Typ-
ical values of TCR triggering threshold TR are in the range of
5–15 s (29).
A
B
FIGURE 1 |TCR/pMHCI/CD8 interactions represented in the model.
(A) Kinetics of TCR/pMHCI/CD8 complex formation. TCRs and CD8s are
located on the T-cell side and pMHCIs on the APC side. Four possible states
are shown: in (I) and (II), pMHCI is not bound to CD8 whereas in (III) and
(IV), pMHCI is bound to CD8; in (I) and (III), pMHCI is not bound to TCR/CD3
whereas in (II) and (IV), pMHCI is bound to TCR/CD3. Transition rates
between these four states are indicated with forward rates labeled as λi
and backward rates labeled as λ− i (where i =1, 2, 3, 4). The white circles in
the tails of the TCR/CD3 complex represent the ITAMs, which are present
on the cytoplasmic tails of the γ, δ, the two ε, and the two ζ polypeptide
chains of the CD3 complex; only one such tail is indicated here, for clarity.
There are n such ITAMs, with only three shown here for the sake of clarity.
This part of the kinetic scheme is assumed to be in equilibrium. (B)The
TCR/pMHCI bound states (II) and (IV) are further subdivided into n states
each depending on the number of phosphorylated ITAMs, resulting in a
Markov chain. The triggered states are the right-most ones where all n
ITAMs have been phosphorylated (indicated as filled-in circles). At each
state a reversal (at rate λ−1 or λ−4) to the unbound states (I) or (III),
respectively, can occur. Transitions between the sequences occur at rates
λ2 and λ−2. Left-to-right transitions within the sequences correspond to
ITAM phosphorylation by kinases such as p56lck and ZAP-70, at rate
nλ=n/TR in the sequence with CD8 unbound and at rate nλ∗ = n/T ∗R in the
chain with CD8 bound. The Markov chain serves to calculate the TCR
triggering probability and is not assumed to be in equilibrium.
KINETIC EQUATIONS
The model describes the kinetics of the interactions between the
TCR, pMHCI molecules, and co-receptor CD8 in the contact area
between a T-cell and an APC. This area is occupied by TCRs and
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CD8s on the T-cell side and by pMHCIs on the APC side, whereby
CD8 binds pMHCI at a distinct site of the TCR/pMHCI complex.
ITAMs are located on the ζ-chains of the CD3 complex associated
with the TCR and are represented schematically in Figure 1B.
Interactions between TCR, pMHCI, and CD8
Key quantities in the model (summarized in Table 1) are the den-
sities of free receptors on the T-cell and free ligands on the APC,
which can also form complexes with the receptors. The surface
densities of the TCR, CD8, and pMHCI molecules are subject to
the following conservation laws:
MT = M +MR +MX +MXR , (1)
XT = X +MX +MXR , (2)
RT = R +MR +MXR , (3)
which state that for each species, the total density must equal the
sum of all bound forms plus the free density. We define pseudo-
unimolecular association rates λi(i= 1, . . ., 4) as follows (see
Figure 1A):
λ1 = Λ1R, λ2 = Λ2X , (4)
λ3 = Λ3X , λ4 = Λ4R, (5)
where Λ1−Λ4 are the two-dimensional association rates
(cm2s−1) for TCR/pMHCI or CD8/pMHCI binding. Two-
dimensional dissociation constants (cm−2) are defined as follows:
K1 = λ−1
λ1
R, (6)
K2 = λ−2
λ2
X , (7)
K3 = λ−3
λ3
X , (8)
K4 = λ−4
λ4
R, (9)
In order for a system of reactions to be in thermal equilibrium,
each individual reaction must be at equilibrium (the principle of
detailed balance):
λ1M = λ−1MR , λ2MR = λ−2MXR ,
λ3M = λ−3MX , λ4MX = λ−4MXR , (10)
from which it follows that K 1K 2=K 3K 4. Combining this with
the conservation laws with we obtain:
M = MT
C
, MR = MTλ1
Cλ−1
,
MX = MTλ3
Cλ−3
, MXR = MTλ1λ2
Cλ−1λ−2
,
(11)
where
C = 1+ λ1
λ−1
+ λ3
λ−3
+ λ1λ2
λ−1λ−2
. (12)
Table 1 | Model parameters and variables.
M Free pMHCI density
MR TCR/pMHCI density without CD8 bound
MX pMHCI/CD8 density without TCR bound
MXR TCR/pMHCI/CD8 density
X Free CD8 density
R Free TCR density
MT Total pMHCI density
XT Total CD8 density
RT Total TCR density
These results can also be expressed in terms of standard affinity
constants:
MR = MT R
K1 + R + XK1/K3 + RX/K2 ,
MX = MT X
K3 + X + RK3/K1 + RX/K4 ,
MXR = MT XR
K1K2 + RK2 + XK4 + RX .
(13)
The co-receptor CD8 modulates the rate of TCR triggering.
Three major modulatory functions of the co-receptor have been
documented: modulation of TCR/pMHCI on-rate, TCR/pMHCI
off-rate, and of the ITAM phosphorylation rate. These effects can
be represented by dimensionless multipliers.
(i) enhanced TCR/pMHCI on-rate:
Λ4 = γonΛ1 where γon ≥ 1;
(ii) reduced TCR/pMHCI off-rate:
λ−4 = γoffλ−1 where 0 < γoff ≤ 1;
(iii) increased phosphorylation rate, which is equivalent to a
reduced TCR triggering threshold T ∗R
λ = γRλ∗, where γR ≤ 1 andλ = 1TR andλ∗ = 1T ∗R . (14)
It is sometimes convenient to combine the on-rate and off-rate
effects into a single coefficient, as follows:
γkin = γoff
γon
= K4
K1
= K2
K3
, where 0 < γkin ≤ 1. (15)
From equation (15), we have γkin≤ γoff . We rewrite MR, MX,
and MXR, as given by equation (13), in terms of γkin:
MR = MT R/K1
1+ R/K1 + X/K3 + RX/ (K1K3γkin) ,
MX = MT X/K3
1+ R/K1 + X/K3 + RX/ (K1K3γkin) ,
MXR = MT RX/ (K1K3)
γkin(1+ X/K3 + R/K1)+ XK3/ (RK1) .
(16)
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To non-dimensionalize this system, we introduce the following
dimensionless quantities:
x = X
K3
, r = R
K1
, xT = XT
K3
, rT = RT
K1
,
κ = K1
K3
, mT = MT
K1
. (17)
It follows from equation (17) that MT/K 3= κmT. By equa-
tions (16) and (17), we have the following non-linear system of
equations that determines the surface densities of free and bound
receptors of all species:
xT = x + κmT x
1+ x + r + xr/γkin + κmT
xr
γkin(1+ x + r)+ xr ,
rT = r +mT r
1+ x + r + xr/γkin +mT
xr
γkin(1+ x + r)+ xr .
(18)
This system is readily solved numerically for x and r, given the
parameters γkin, κ, rT, and mT.
The TCR triggering rate
The functional sensitivity of the TCR is represented in the present
model as the rate at which TCR/CD3 complexes attain signalo-
some status. To calculate this TCR triggering rate, which we shall
denote by W, consider the Markov chain as depicted in Figure 1B,
which is best thought of as a system of two coupled linear Markov
chains. The TCR/CD3 complex has to undergo n phosphoryla-
tions for the TCR to be triggered. When the co-receptor is not
bound to the TCR/pMHCI complex, individual phosphorylation
steps proceed at rate n/TR≡ nλ whereas when the co-receptor is
engaged, this rate is n/T ∗R ≡ nλ∗ ≥ nλ. The factor n arises simply
as a matter of scaling, so that the average time to progress through
the chain of phosphorylations equals TR.
In reality, signalosome formation involves several other types
of event besides ITAM phosphorylation, such as binding of ZAP-
70, engagement of LAT, and so on. To avoid cumbersome notation
we shall formulate the model as if ITAM phosphorylation were the
only type of event; the essential theory is not materially affected by
this simplification. We do not assume an equilibrium state for the
Markov chain: the complex starts at zero phosphorylations at the
beginning of every encounter with a pMHCI ligand and proceeds
forward stochastically.
The pMHCI/TCR/CD3 complex may not attain the nth state
(triggered state), but instead the pMHCI/TCR engagement may
terminate, which happens at rate λ−1 when the co-receptor is not
bound and at rate λ−4≤λ−1 when the co-receptor is engaged.
We assume that upon TCR/pMHCI dissociation the CD3 com-
plex reverts to the basal state of zero ITAM phosphorylations
sufficiently rapidly that the TCR/CD3 complex will be in this com-
pletely unphosphorylated state when the next encounter with a
pMHCI molecule occurs. Essentially, this means that the CD3
complex is more susceptible to the action of phosphorylases
and/or less susceptible to the action of kinases when the TCR
is not engaged. A mechanistic explanation underpinning this
assumption lies outside the scope of the present model.
The probability that the TCR/CD3 complex will undergo
another ITAM phosphorylation is given by
P0a =
nλ
λ−1 + nλ+ λ2 (19)
in the case where the co-receptor CD8 is not engaged and by
P∗a =
nλ∗
λ−4 + nλ∗ + λ−2 (20)
when CD8 is engaged. The following expression gives the proba-
bility that the system switches from the chain with CD8 unbound
to the chain with CD8 bound:
P0b =
λ2
λ−1 + nλ+ λ2 (21)
whereas the system will switch from CD8-unbound to CD8-bound
with probability
P∗b =
λ−2
λ−4 + nλ∗ + λ−2 . (22)
TCR triggering requires completion of all steps before the
TCR/pMHCI complex comes apart. We shall find an expression
for the probability that the CD3 complex will ultimately attain
completion when starting from i completed steps. Let P0i denote
this probability for the case with CD8 unbound andP∗i for the case
with CD8 bound. The TCR triggering probability is then found
as P00 if CD8 is unbound when pMHCI docks the TCR, and P∗0 if
CD8 is bound. These triggering probabilities allow us to calculate
the TCR triggering rate W. In particular, W can be expressed as the
rate at which TCR/pMHCI complexes dissociate, times the prob-
ability that whenever a given TCR/pMHCI docking commences,
the CD3 complex is ultimately triggered (the probabilities P00 and
P∗0 ). In formula, this statement is represented as follows:
W = Mλ1P00 +MXλ4P∗0 (23)
which, by the principle of detailed balance, can be rewritten in
terms of dissociation rates, as follows:
W = Rλ−1P00 +MXRλ−4P∗0 . (24)
The law of total probability yields the following system of
coupled difference equations:[
P0i−1
P∗i−1
]
= 1
1− P0bP∗b
[
P0a P0bP
∗
a
P∗bP
0
a P∗a
] [
P0i
P∗i
]
(25)
which can be solved to give[
P00
P∗0
]
= 1
(1− P0bP∗b)n
[
P0a P0bP
∗
a
P∗bP
0
a P∗a
]n [
1
1
]
(26)
where we have used the boundary condition
P0n = P∗n = 1 . (27)
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This boundary condition expresses the basic assumption that
triggering is attained when the sequence has been completed. To
render the equations dimensionless, we introduce the following
parameters:
ν = Λ2K3
λ
, α = λ−1
λ
, δ = λ−2
λ
. (28)
The scaled (dimensionless) TCR triggering rate is then given by
the following expression:
w = α(eP00 + ζγoffP∗0) (29)
where
w = W
K1mTλ
; (30)
ε = r
1+ x + r + xr/γkin ; (31)
ζ = xr
γkin(1+ x + r)+ xr . (32)
The scaled TCR triggering rate w depends on ten dimensionless
parameters (Table 2).
STATISTICAL FORMULATION OF TCR DEGENERACY
To express TCR degeneracy mathematically, we consider the dis-
tribution of the triggering rate over the set of peptide ligands.
This is just the set of wij-values for a given TCR clonotype i over
pMHCI ligands j. The distribution can be represented by plotting
the probability P(wij >ω) as a function of ω. Such a graph shows
how many randomly selected peptides would have triggering rate
w larger than a set value ω. Let Tij denote the mean dwell time
of the TCR/pMHCI interaction for TCR clonotype i and pMHCI
species j so that T−1ij is the TCR/pMHCI off-rate λ−1 (we have
thus far suppressed subscripts for clone i and ligand j to keep
notation uncluttered). Arrhenius theory furnishes the following
relationship with the dissociation energy barrier ∆Uij:
Tij = T0 exp(∆Uij), (33)
where T 0 is the frequency factor and ∆Uij is expressed in Boltz-
mann units. We assume that the dissociation energy barrier arises
as a result of a large number of individual reaction steps at the
TCR/pMHCI interface. If these combine additively, then the Cen-
tral Limit Theorem implies that ∆Uij has a Gaussian distribution.
Letting uij=∆Uij− ln{TR/T 0} we have uij∼N (−µ, σ2), where
µ> 0 and σ are the underlying parameters of the normal distribu-
tion N. The assumption that the mean is negative is a consequence
of the fact that for the vast majority of TCR/pMHCI complexes
the mean dwell time is less than the typical time required to com-
plete the chain of ITAM phosphorylations. It now follows that
the dimensionless parameter α, associated with the TCR/pMHCI
off-rate, is log-normally distributed.
RESULTS
We investigated the effect of variations of the total CD8 density
on the functional sensitivity of hypothetical ligands with various
Table 2 | Dimensionless (scaled) parameters that govern functional
sensitivity.
mT Scaled total pMHCI density
xT Scaled total CD8 density
rT Scaled total TCR density
α Scaled TCR/pMHCI off-rate without CD8 bound
δ Scaled pMHCI/CD8 off-rate with TCR bound
ν Scaled kinetic effect of pMHCI/CD8 interactions with and without TCR
κ Ratio of dissociation constants K 1 and K 3
γoff Factor by which CD8 modulates TCR/pMHCI off-rate
γkin Factor by which CD8 modulates the TCR/pMHCI affinity
γR Factor by which CD8 modulates the TCR triggering threshold
TCR/pMHCI off-rates. All variables and parameters are dimen-
sionless (scaled) in the model simulations. The scaled parameters
are summarized in Table 2 and their scaling is defined in equations
(14), (15), (17), and (28).
LIGAND FOCUSING AND CD8-MEDIATED CONTROL OF DEGENERACY
Figure 2A shows the scaled functional sensitivity w as a function
of scaled total CD8 density xT with different scaled TCR/pMHCI
off-rates α. A striking feature is the dip at xT≈ 50, suggesting that
at this CD8 density the T-cell is minimally responsive. As the scaled
total CD8 density increases above xT≈ 50, the scaled functional
sensitivity increases for all hypothetical ligands.
It can be observed that a ligand with α= 2.5 (solid line)
and a ligand with α= 0.5 (dotted line) show opposing changes
in the scaled functional sensitivity: a ligand that is less potent
at low CD8 becomes more potent at high CD8 and vice versa.
Hence, changes in CD8 expression levels can differentially affect
the potency of ligands, each of which is potentially a strong ago-
nist. In effect, the T-cell can tune in on a specific ligand and thus
control ligand promiscuity. We call this the principle of ligand
focusing.
The corresponding degeneracy curves P(w >ω) for different
scaled total CD8 densities are shown in Figure 2B. The effect of
the increase in co-receptor density on the sensitivity and degener-
acy is indicated: sensitivity is a change in the horizontal direction
(modulating the triggering threshold) and degeneracy is a change
in the vertical direction (controlling cross-reactivity). As the scaled
total CD8 density increases up to xT≈ 50, the degeneracy curves
P(w >ω) move to the left from the curve without CD8 (xT= 0):
degeneracy and sensitivity decrease. By contrast, as the scaled total
CD8 density increases above xT≈ 50, the degeneracy curves move
to the right, which means that degeneracy and sensitivity both
increase. The overall effect is that the T-cell becomes more degen-
erate as CD8 levels increase. Thus, in addition to the focusing
effect, the co-receptor also governs the overall degeneracy of the
T-cell.
A high degree of degeneracy can increase the risk autoimmune
disease. On the other hand, too low a degree of degeneracy could
compromise the immune system’s ability to mount a timely and
efficient response. To analyze these risks, suppose that the T-cell
is activated if its integrated TCR triggering rate exceeds a certain
value, termed cellular activation threshold. A simple model is to
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A B
C
FIGURE 2 | (A) Scaled functional sensitivity w as a function of scaled total
CD8 density xT for various scaled TCR/pMHCI off-rates α. (B) Degeneracy
curves P(w >ω) for various scaled total CD8 density xT. (C)The probability
P(w >ω) as a function of CD8 density xT, at a set value of functional
sensitivity ω=0.12. The operating range of the probability P is shown as a
function of xT with dashed lines at P(w >0.12)=10−8 and P(w >0.12)= 10−5.
Parameter values: δ=300, ν=0.5, n=100, γkin =0.5, γoff =0.5, γR =0.3,
κ=5, mT =10, rT =10. The log-normal distribution has mean 2 and SD 0.2.
assume that the T-cell is activated if
Zj TI wij > Wact (34)
where Zj is the presentation level of ligand j, TI is the duration of
the T-cell:APC interaction, and W act is the activation threshold.
For a given Zj and TI, there is a critical wij which is the mini-
mum value required to satisfy equation (34). Suppose for instance
that this corresponds to wij= 0.12. The corresponding probabil-
ities P(w > 0.12) are plotted in Figure 2C. Given the estimates
of the TCR repertoire size, normal immune function is proba-
bly confined to an operating range of probabilities 10−8 to 10−5.
Figure 2C shows how the level of CD8 can regulate the respon-
siveness to remain within this band; if the activation probability
drops below this range, the risk of not responding to a pathogen
looms, whereas at much elevated activation probabilities, the risk
of autoimmunity is heightened.
MODES OF CD8-MEDIATEDMODULATION OF FUNCTIONAL SENSITIVITY
Figures 3 and 4 exhibit the co-receptor effect on functional sen-
sitivity in two parameter scenarios, where we assume a weak
(ν= 0.05) or a strong (ν= 300) kinetic effect of pMHCI/CD8
interactions, respectively. When the kinetic parameter ν is small,
increasing the levels of CD8 on the T-cell surface leads to enhanced
functional sensitivity of ligands with α> 1, as shown in Figure 3A.
By contrast, ligands with low off-rates (α< 1) become less potent
when CD8 levels are increased. These opposite effects demonstrate
CD8-mediated focusing on particular ligands.
Figure 3B shows the effect of increasing CD8 levels on a lig-
and that is optimal in the absence of CD8. When the modulatory
effect of CD8 on the TCR triggering threshold is modest (γR
is near 1), the ligand becomes less potent as levels of CD8 are
increased. On the other hand, when CD8 has a strong effect on
the TCR triggering threshold (low γR, since the time required to
trigger the TCR/CD3 complex is shortened), increasing the levels
of CD8 on the cell surface enhances the functional sensitivity to
the ligand.
The effect of CD8 levels on functional sensitivity is shown in
Figure 4A. For each ligand, there is an optimal CD8 level which
depends on that ligand’s TCR/pMHCI off-rate α. This shows that
the T-cell can favor the signaling strength of a given ligand by
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A B
FIGURE 3 | Scaled functional sensitivity w as a function of scaled
total CD8 density xT. (A) Curves for various values of the scaled
TCR/pMHCI off-rate α. (B) Curves for various values of the factor γR by
which CD8 modulates the TCR triggering threshold. Parameter values in
(A,B): δ=2.5, ν=0.05, n=100, γkin =0.5, γoff =0.5, γR =0.5, κ=1,
mT = 10, rT =10, α=1.
A B
FIGURE 4 | Scaled functional sensitivity w as a function of scaled total
CD8 density xT. (A) Curves for various values of the scaled TCR/pMHCI
off-rate α. (B) Curves for various values of the dimensionless factor γoff
expressing the modulatory effect of CD8 on the TCR/pMHCI off-rate.
Parameter values in (A,B) δ=3, ν=300, n=100, γkin =0.05, γoff = 0.2,
γR =0.5, κ=2, mT =10, rT =10, α=2.
adjusting the density of CD8 molecules on its surface. As one
would expect, the modulatory effect is most profound when the
relative effect that the co-receptor exerts on the TCR/pMHCI off-
rate is greatest; this is shown in Figure 4B. When CD8 alters the
off-rate strongly, the functional sensitivity is strongly depressed
when CD8 levels are increased beyond the optimal level, whereas
for a moderate value of the modulatory multiplier γoff , the func-
tional sensitivity remains at near-optimal levels when CD8 levels
are increased. The value of γoff may be expected to be different
for different TCR/ligand combinations. In particular, when CD8
makes a substantial contribution to the binding energy, the multi-
plier γoff will be low, and the co-receptor role in governing ligand
optimality will be more pronounced.
CO-RECEPTOR MODULATION OF DEGENERACY VIA ALTERED
pMHCI/CD8 BINDING AFFINITY
Wooldridge et al. (5, 30, 31) have shown that (i) increased
pMHCI/CD8 interaction results in enhanced recognition of
pMHCI by cytotoxic T-cells and (ii) increased pMHCI/CD8 inter-
action impairs pMHCI recognition specificity, suggesting that the
pMHCI-CD8 interaction is essential in regulating the balance
between optimal T-cell cross-reactivity and T-cell antigen speci-
ficity (32). These findings suggest that an optimal pMHCI/CD8
strength exists that yields maximum pMHCI sensitivity without
loss of specificity. Motivated by these results, we consider a hypo-
thetical scenario in which pMHCI mutant molecules with altered
binding affinity for CD8 modulate TCR degeneracy.
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In keeping with (17), the following pMHCI mutants are
considered: A245V representing weak pMHCI/CD8 affinity
(KD= 498µM), wild-type (KD= 137.1µM), Q115E represent-
ing slightly enhanced affinity (KD= 97.94µM), and A2/α3kb
with enhanced affinity (KD= 10.87µM). These values are based
on Surface Plasmon Resonance experiments and should be
regarded as “three-dimensional,” relating to the ligands in solu-
tion. However, the TCR/pMHCI interaction takes place in the
“two-dimensional” environment of the T-cell:contact area, which
essentially reduces spatial degrees of freedom of molecular motion
and, moreover, introduces dynamics related to the forces that
constrain the molecules to this environment, such as rotations
with respect to the membrane plane, membrane fluctuations, and
the translational motion of the membranes themselves (33). Fur-
thermore, cooperativity interactions, such as the involvement of
the co-receptor, may be profoundly altered. As a result, the rate
constants can be markedly different in the “two-dimensional”
environment; in particular, two-dimensional dissociation rates can
be substantially faster (28). The ratio between the three- and two-
dimensional affinities is a length measure, denoted h and called
the confinement length (34, 35). Wu et al. (33) demonstrated that
h is proportional to the range of motion available to the free forms
of the interacting ligands along the spatial axis perpendicular to
the two parallel membranes. Thus the inter-membrane separation
distance provides an upper bound, and if the ranges of motion are
broadly comparable, we may assume that the confinement length
is roughly the same for all mutants involved.
The two-dimensional dissociation constant for pMHCI/CD8
interaction without TCR bound, K 3, appears in the scaled para-
meters κ, xT, and ν. Hence, by taking K 3 to be proportional to
KD for a given pMHCI mutant, we can simulate the impact of
the altered pMHC/CD8 binding affinity on TCR degeneracy and
sensitivity. Figure 5A shows the scaled functional sensitivity w as a
function of scaled TCR/pMHCI off-rateα for the four hypothetical
pMHCI mutants.
The co-receptor CD8 can modulate the specificity of antigen
recognition, as shown in Figure 5B. Each TCR degeneracy curve
corresponds to a given pMHCI mutant, where the one with the
strongest pMHCI/CD8 binding affinity (A2/α3kb) is the most
degenerate, with the largest antigen sensitivity. The three regions
are a schematic representation of the overall pattern of CD8+ T-
cell antigen specificity, as defined by Cole et al. (32). With increas-
ing strength of pMHCI/CD8 affinity, as indicated by the arrow,
the recognition efficiency of partially CD8-dependent ligands is
enhanced and the spectrum of CD8+ T-cell antigen degeneracy
becomes wider. Enhancing the kinetic effect of pMHCI/CD8 inter-
actions (setting ν 1) results in the reversed pattern, as shown in
Figure 5C.
Whereas in the MHC-limited kinetic regime, the behavior is as
shown in Figure 5B, the degeneracy curves for the various mutants
overlap in the TCR-limited regime. This suggests that excess levels
of ligand, relative to the available levels of TCR molecules, can
diminish the importance of the interaction between pMHCI and
CD8. In principle, this endows the APC with a means to “override”
the ligand focusing exerted by the T-cell, allowing a professional
APC, such as a dendritic cell, to force a naïve T-cell, with which it
has conjugated, to be maximally degenerate.
DISCUSSION
The co-receptors CD4 and CD8 are glycoproteins that modulate
the interactions of the TCR with pMHCI and pMHCII mole-
cules, by binding to invariant sites on these molecules (10). It
is well-established that the co-receptors differentially regulate the
responsiveness of the TCR to the ligand and thereby modulate TCR
specificity (1). In particular, CD8 is known to affect both the on-
rate and the off-rate of the TCR/pMHCI interaction (17, 36). This
allows the co-receptor to differentially regulate the strengths of
the various potentially strong agonists of the TCR. This accords
with the finding that the strength of pMHCI/CD8 interaction
is a determinant of T-cell degeneracy (5). This ligand focusing
effect remains to be observed experimentally, to the best of our
knowledge. Perhaps this is only to be expected inasmuch as the
experimenter has to search for ligands that are sub-optimal under
standard conditions but become better or worse agonists when
CD8 levels are manipulated. Research is presently underway to
identify such ligands and we anticipate that the phenomenon
will be confirmed and eventually emerge as a pervasive “design
principle” of cellular adaptive immunity.
Co-receptor-directed ligand focusing may allow the T-cell
response to an antigen challenge to undergo an adaptive evolu-
tion that would be functionally analogous to affinity maturation
in B-cell immunity. Moreover, CD8 modulation could allow for
an elevated degeneracy among the earliest responding clones. This
would ensure that at least one or more responding clones are acti-
vated sufficiently early in the course of the infection. Moreover, a
gradual restriction of the degeneracy, coupled with an increase in
functional sensitivity to the salient epitope, would then reduce the
degeneracy of the response, which would gradually evolve from
oligoclonal to one that is dominated by an optimally tuned single
clone.
Disrupting the pMHCI/CD8 interaction impairs the ability of
T-cells to recognize antigens. In particular, T-cell activation can be
abrogated if the pMHCI/CD8 interaction is blocked (32), whereas
increases in pMHCI/CD8 affinity have the opposite effect (37, 38).
The contribution of CD8 to increase functional sensitivity appears
to be crucial for weaker agonists (36). A comprehensive evaluation
of clonal CD8+ T-cell degeneracy using combinatorial peptide
libraries and APCs expressing mutant HLA A∗0201 molecules
with altered pMHCI/CD8 affinity has shown that the co-receptor
enhances T-cell degeneracy by increasing the range of agonist lig-
ands that can elicit T-cell activation (5). Furthermore, increasing
the affinity of CD8 for HLA A∗0201 by at least an order of mag-
nitude resulted in the loss of cognate antigen specificity (5, 31).
The affinity of the pMHCI/CD8 interaction may be directly linked
to TCR degeneracy: increased pMHCI/CD8 interaction enhances
CD8+ T-cell antigen sensitivity, but reduces CD8+ T-cell antigen
specificity (32). This agrees with our main finding that variation
of the co-receptor effect regulates the degree of T-cell degeneracy
and antigen specificity.
A cornerstone of the present theory is that a certain amount
of degeneracy is unavoidable, in view of the vast universe of
possible peptides and the relatively modest number of TCR clono-
types that even a large mammal might be able to maintain in its
standing repertoire. Moreover, salient epitopes, those associated
with a disease state, and non-salient ones, such as self-peptides
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A B
C
FIGURE 5 | (A) Scaled functional sensitivity w as a function of scaled
TCR/pMHCI off-rate α. (B) Degeneracy curves P(w >ω) for HLA A∗0201
mutants with altered binding affinity for CD8: A245V (dotted line), wild-type
(semi-dashed line), Q115E (dashed line), and A2/α3kb (solid line). The three
regions represent the overall pattern of CD8+ T-cell antigen specificity and the
arrow indicates the strength of pMHCI/CD8 interaction. (C) Degeneracy
curves P(w >ω) for HLA A∗0201 mutants with altered binding affinity for CD8.
The parameter values are the same as in A except for ν= 10. Parameter
values in (A,B): δ=0.2, ν=0.05, n=100, γkin =0.5, γoff =0.5, γR =0.2, κ=1,
mT = 10, rT = 10, xT =10. The log-normal distribution has mean 5 and SD 0.5.
for which immune tolerance is required, will of necessity be
“finely interleaved” subsets of the peptide universe (a mathe-
matician would say that one subset is “dense” in the other),
lest the tolerant subset forms a target for the rapidly evolving
pathogens: the system cannot work if molecular mimicry is read-
ily attained. From these two premises, it follows that a TCR must
be degenerate, and also that this degeneracy must be suscepti-
ble to exquisite modulation. Against this line of reasoning a case
could be made that the size of the ligand universe is effectively
much smaller. For instance, if one considers n-mer peptides that
are anchored to the MHC binding groove at a positions, and
the region of the TCR that interacts with the peptide (roughly
speaking, the CDR3 loop) makes contacts with c of the amino
acid residues in the m-mer (so that 0<m≤ n− a), then there
are 20m(n− a)!/(m!(n− a−m)!) effectively distinct pMHCI lig-
ands as seen by the TCR. To give an extreme example, with n= 9,
a= 2, and m= 1, this works out as just 20× 7= 140 distinct lig-
ands. Perhaps the estimate m= 4 is more realistic: this gives only
204× 35= 5.6× 106 functionally distinct ligands, which is of the
same order as the TCR repertoire size. Whereas there may be
some merit to this argument, its underlying image, essentially of
CDR3 as a tape recorder head that interacts with only m amino
acid residues and is indifferent to the n−m other ones, is a
gross oversimplification. The physical behavior of the m amino
acid residues at the contact sites cannot fail to be influenced
by the n−m remaining ones (including the a anchor residues).
This is overwhelmingly apparent not just from the basic prin-
ciples of molecular dynamics, but also from the typical results
obtained with combinatorial peptide library scans. A case in
point is the finding that changes at the anchor position result in
changes in the center of the peptide and therefore influence TCR
binding (39, 40).
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The present model indicates that intermediate levels of CD8 are
associated with the lowest functional sensitivity. This suggests the
following mechanism to maintain quiescent (naïve) T-cells in a rel-
atively unresponsive state. When the T-cell receives the appropriate
stimuli, it either up-regulates or down-regulates the co-receptor
and a specific subset of its potential agonists “comes into focus.”
Such signals are known to be transmitted via cytokine profiles in
the T-cell’s surroundings (15) as well as costimulatory receptor-
mediated signals transmitted by professional APCs (41). When no
harm is detected, the default response of the naïve T-cells would
be to “de-tune” whenever a strong signal is registered. Detuning
of T-cells via alterations of CD8 expression levels, under control
of cytokine stimuli, has been reported (42) and the connection
between functional sensitivity, tolerance, and CD8 expression lev-
els is well-established (14, 43, 44). On the other hand, when harm is
detected and transmitted via a pro-inflammatory cytokine profile,
the T-cell’s response would invert and the tendency would become
to “tune in” to any supra-threshold stimulation. On a molecular-
cellular level, this would involve a scanning mechanism whereby
the stimulus would make the cell enter a mode in which it gradu-
ally alters the CD8 expression level whilst the received TCR signal
(which will shift in magnitude as the CD8 level changes) feeds
back onto this pathway. To the best of our knowledge, the molecu-
lar details of such a regulatory pathway have not been elucidated to
date. However, we believe that it is well within the regulatory capa-
bilities of cellular signaling networks; we have previously discussed
similar mechanisms in more depth (45, 46).
Whilst the model includes the key components of TCR trig-
gering, many important aspects have been omitted. In particular,
we have neglected the spatial dynamics of TCR, CD8, and pMHCI
within the immunological synapse, where the relative concentra-
tions of p56lck and CD45 will determine how quickly partially
phosphorylated TCR/CD3 will reset to the basic state (47). A
functional consequence of the exclusion of phosphorylases, for
instance, could be the ability of the TCR/CD3 complex to be trig-
gered over subsequent interactions with ligands that would in a
normal context only have weak functional sensitivity.
In addition to kinetics of the interaction between TCR, MHCI,
and CD8, we have only considered ITAM phosphorylation steps.
It is well known that phosphorylated ITAMs orchestrate the acti-
vation of the Src-related protein tyrosine kinases which initiate
TCR signaling. These kinases induce tyrosine phosphorylation of
several polypeptides, including the transmembrane adaptors. Pro-
tein tyrosine phosphorylation subsequently leads to the activation
of multiple pathways such as ERK, NF-κB, and NFAT (48, 49).
Moreover, negative regulation of TCR signaling is key to avoiding
hyper-activation. Notwithstanding the additional layers of com-
plexity which our simple model ignores, we believe that the system
of two linked proofreading chains as presented here does capture,
in a qualitative sense, the essence of TCR triggering.
In summary, the present findings suggest that the co-receptor
CD8 can differentially modulate functional sensitivity to its poten-
tial agonists, thereby modulating TCR degeneracy in a tunable
fashion. The ligand focusing mechanism would allow each T-cell
to have a wide range of potential agonists, even while only one
of these would be a ligand of high functional sensitivity at any
particular moment in time.
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